May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol

  • Authors:
    • Massimo Serra
    • Michela Pasello
    • Maria Cristina Manara
    • Katia Scotlandi
    • Stefano Ferrari
    • Franco Bertoni
    • Mario Mercuri
    • Thor Andreas Alvegard
    • Piero Picci
    • Gaetano Bacci
    • Sigbjørn Smeland
  • View Affiliations

  • Published online on: December 1, 2006     https://doi.org/10.3892/ijo.29.6.1459
  • Pages: 1459-1468
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim was to evaluate the clinical impact of P-glycoprotein in primary non-metastatic high-grade osteosarcoma patients, treated with neoadjuvant chemotherapy protocols. P-glycoprotein was assessed by immunohistochemistry on paraffin-embedded tissue samples collected at time of diagnosis from 94 osteosarcoma patients, treated with the Italian Sarcoma Group/Scandinavian Sarcoma Group 1 (ISG/SSG 1) protocol. P-glycoprotein-positivity at diagnosis was found in 53/94 ISG/SSG 1 cases (56%) and emerged as the single factor significantly associated with an unfavourable outcome from survival and multivariate analyses. A comparative analysis of the subgroup of 94 patients considered for P-glycoprotein evaluation and the whole series of ISG/SSG 1 patients showed that this marker retained its prognostic value also in the latter group. In osteosarcoma patients treated with doxorubicin-based chemotherapy protocols, P-glycoprotein overexpression at diagnosis is an important adverse prognostic factor for outcome. P-glycoprotein evaluation can therefore constitute the basis for stratifying, at diagnosis, osteosarcoma patients for whom alternative treatments may be considered.

Related Articles

Journal Cover

December 2006
Volume 29 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Bacci G, et al: May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 29: 1459-1468, 2006
APA
Serra, M., Pasello, M., Manara, M.C., Scotlandi, K., Ferrari, S., Bertoni, F. ... Smeland, S. (2006). May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal of Oncology, 29, 1459-1468. https://doi.org/10.3892/ijo.29.6.1459
MLA
Serra, M., Pasello, M., Manara, M. C., Scotlandi, K., Ferrari, S., Bertoni, F., Mercuri, M., Alvegard, T. A., Picci, P., Bacci, G., Smeland, S."May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol". International Journal of Oncology 29.6 (2006): 1459-1468.
Chicago
Serra, M., Pasello, M., Manara, M. C., Scotlandi, K., Ferrari, S., Bertoni, F., Mercuri, M., Alvegard, T. A., Picci, P., Bacci, G., Smeland, S."May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol". International Journal of Oncology 29, no. 6 (2006): 1459-1468. https://doi.org/10.3892/ijo.29.6.1459